pharmaphorum

SEPTEMBER 13, 2022

Noticing a pattern in the lymph nodes and spleen that indicated the appearance of disease, he published his findings in a paper entitled, ‘On Some Morbid Appearances of the Absorbent Glands and Spleen’. 1847 – Virchow links tumours and white blood cells. 1844 – First reported case of multiple myeloma.

Food and Drug Administration 86

Food and Drug Administration Patients Engineering Physicians 86

pharmaphorum

JUNE 29, 2022

There’s no reason to suppose that the innovative launches coming in from 2020 have suddenly become less innovative and significant in terms of commercial potential; most launches are entering the same types of therapy area – oncology, immunology and rare diseases – as before the pandemic, and the unmet need in these areas remains high.

Doctors 59

Doctors Medicine Marketing Prescription 59

pharmaphorum

OCTOBER 4, 2022

During the first stage of the initiative, more than 2,000 research papers were published, 49 clinical trials were carried out, and more than 30 patents were filed through the support of the US National Cancer Institute (NCI). These datasets are critical as a means to identify how molecular information affects clinical outcomes.”

Electronics 95

Electronics Patients Management Insurance 95

Evolve Your Success

MAY 2, 2023

It was the days of the big hair, the white uniforms, and the caps. We had paper charts. I worked on an oncology floor and we did it on the floor. They got their paper roots on there. How long were you a nurse? Where were you a nurse? Give us a little bit of that story. That’s how long ago. I still do. They’re online.

Medical sales 98

Medical sales Medical Sales Management 98

Evolve Your Success

JULY 25, 2023

I like to plan my days on a Friday afternoon, with the caveat and little star on my paper that this is the plan. I finally put my hands up and my white flag. It can be two days before a surgery schedule forgets to call and block time opens up or when we are doing some of the pelvic trauma stuff. There is also plan B, C, and D.

Sales 52

Sales Medical sales Medical Competition 52

Evolve Your Success

AUGUST 2, 2022

We do a lot of that type of stuff in oncology, so there is a wide range but of good devices. By this time, I had an idea that some people back then were making some paper, and I was like, “I need to get to that spot. She happens to be a White lady. It’s a lot of bread and butter, repetitive stuff you find on any OR board.

Sales 52

Sales Medical Medical sales Medical sales reps 52

Pharmaceutical Technology

MARCH 17, 2023

Between 2012 and 2022, the number of oncology risk sharing agreements increased massively by 498%. Watt said risk sharing agreements in oncology made up almost 50% of all pharmaceutical risk sharing agreements, as per a GlobalData analysis. This may be because access to oncology drugs varies widely across the world, she added.

Marketing 102

Marketing Pharma Pharmaceutical Healthcare 102

Pharmaceutical Technology

FEBRUARY 20, 2023

Meanwhile, in clinical trials with available race data, white participants account for 59% of trial subjects, more than the combined total for all other racial categories. participation of white subjects. In addition, safety oncology and immunotherapy, which is a focus area for Cerba Research has close ties to virology.

Healthcare 52

Healthcare Healthcare Medicine Biopharma 52

Pharmaceutical Technology

APRIL 6, 2023

Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space.

FDA 52

FDA Food and Drug Administration Medical Food 52

Pharmaceutical Technology

MARCH 8, 2023

Molecular science and technology firm Caris Life Sciences and Incyte have entered a strategic research collaboration to advance the latter’s oncology pipeline. The post Caris signs research partnership with Incyte for oncology pipeline appeared first on Pharmaceutical Technology. Please check your email to download the Whitepaper.

Patients 52

Patients Pharmaceutical Medicine Leads 52

Pharmaceutical Technology

MARCH 9, 2023

Global biopharmaceutical firm UCB and Cancer Research UK have entered a multi-project partnership to advance two of the former’s oncology antibody candidates through clinical trials. It will combine Cancer Research UK’s oncology-focused translational research and clinical development capabilities and the antibody discovery expertise of UCB.

Leads 52

Leads Pharmaceutical Networking Manufacturing 52

Pharmaceutical Technology

MARCH 20, 2023

Oncology and cardiovascular therapies were relatively low with 132 and 118 trials respectively. To learn more about how Oximio is unlocking the clinical trial potential of Africa, download the specially commissioned white paper below. Nigeria was the next highest with 169, followed by 163 in Kenya, and 160 in Uganda.

Distribution 52

Distribution Management Patients Transportation 52

Pharmaceutical Technology

MARCH 20, 2023

We believe that this antibody is a valuable addition to our immuno-oncology portfolio, whether used alone or in combination with our personalised immunotherapies.” “The data presented by OncoC4 on their ONC-392 antibody indicate a differentiated safety profile and encouraging clinical activity in various types of tumours. “We

Food and Drug Administration 98

Food and Drug Administration Food Safety FDA 98

Pharmaceutical Technology

FEBRUARY 20, 2023

This white paper explores the roles immunohistochemistry (IHC), next-generation sequencing (NGS), and circulating tumour DNA (ctDNA) play in non-small cell lung cancer (NSCLC) precision medicine therapy development, and how they help healthcare providers determine the most effective treatment regimens for their patients.

Medicine 52

Medicine Government Healthcare Healthcare 52

Pharmaceutical Technology

MARCH 20, 2023

Aside from a very slight rise in funding for genetic disorder treatments, investors’ order of priorities remains unchanged – with oncology still far and away the most actively funded area of research. But the headline figures are concealing some rising trends. One significant growth area is the rise of genomics.

Pharmaceutical 90

Pharmaceutical Pharma Marketing Manufacturing 90

Pharmaceutical Technology

JANUARY 12, 2023

For more information about how Baxter BioPharma Solutions manufacturing expertise can support your project, dow nload the paper below. . Download this whitepaper to find out more about oncology trends and how Baxter’s oncology contract manufacturing facility in Halle, Germany, minimise the risk of cross contamination.

Manufacturing 52

Manufacturing Biopharma Pharmaceutical Distribution 52

Pharmaceutical Technology

FEBRUARY 24, 2023

AstraZeneca Oncology R&D Biologics Engineering & Oncology Targeted Delivery senior vice-president Puja Sapra said: “We are excited by the opportunity to accelerate the development of CMG901, a potential new medicine for patients with Claudin18.2-expressing expressing cancers.

Biopharma 52

Biopharma Engineering Pharmaceutical Safety 52

Pharmaceutical Technology

JANUARY 10, 2023

Last year, AstraZeneca acquired Neogene Therapeutics and announced a partnership with Huma Therapeutics within the oncology space. By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Prospecting 98

Prospecting Pharma Pharmaceutical Competition 98

Pharmaceutical Technology

FEBRUARY 17, 2023

The non-binding draft guidance gives insight into the agency’s current outlook and recommendations for standard and expedited programs in oncology. The agency proposes that pharma move away from the common maximum tolerated dose (MTD) to trial designs that prioritise drug dosage optimisation at different stages.

FDA 115

FDA Side effects Pharmacology Patients 115

Pharmaceutical Technology

DECEMBER 13, 2022

Koh is Chief Product Officer at Suvoda, a global clinical trial technology company that specialises in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease.

Marketing 104

Marketing Management Patients Healthcare 104

Pharmaceutical Technology

FEBRUARY 28, 2023

This licensing agreement will expand Chipscreen NewWay’s pipeline in the field of antibody drugs and immuno-oncology.” Chipscreen Biosciences CEO and president Dr Xianping Lu said: “Biocytogen’s YH008 has unique mechanisms and outstanding preclinical results.

Biopharma 52

Biopharma Food and Drug Administration Pharmaceutical Sales 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Celnova Pharma is an Argentina-based pharmaceutical company that centres its work around rare diseases, oncology, central nervous system, diabetes and critical care. HRA RD’s new partnership will function to allow HRA RD to launch its rare disease products Ketoconazole HRA and Lysodren across Argentina, Chile and Peru.

Marketing 52

Marketing Pharmaceutical Pharma Pharmaceutical Sales 52

Pharmaceutical Technology

JANUARY 25, 2023

Others, like Elevation Oncology and Fate Therapeutics , have announced similar plans. While it is only January, several companies have already announced cuts and layoffs this year. UK-based biotech ReNeuron announced plans to lay off 40% of its employees , and Cyteir Therapeutics will be firing 70% of its staff.

Marketing 69

Marketing Biopharma Pharma Competition 69

Pharmaceutical Technology

DECEMBER 6, 2022

Within that figure, GlobalData estimates that around 60% of pipeline HPAPIs are developed to target oncology. HPAPIs may now represent more than 30% of the drug development pipeline.

Manufacturing 52

Manufacturing Pharmaceutical Pharmaceutical manufacturing Safety 52

Pharmaceutical Technology

DECEMBER 22, 2022

The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. As part of the decision-making process, they may request further evidence. By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA.

Medicine 52

Medicine Pharma Marketing Distribution 52

Pharmaceutical Technology

APRIL 16, 2023

This is an exciting prospect: oncology, and immuno-therapy in particular, is a driving force behind biotech R&D, with new cancer therapies and molecules accounting for nearly 40% 1 of the industry’s development pipeline. model, download this white paper. To learn more about the Maggie autoinjector and the newer 5.0

Medical 52

Medical Medicine Patients Manufacturing 52

Pharmaceutical Technology

MAY 9, 2023

The shared expertise and resources enables Cerba Research to broaden its services within cell and gene therapy, infectious disease and oncology and access new markets in North America, Asia and Africa, the sites of some of the most exciting growth in clinical trials.

Management 52

Management Patients Marketing Medical 52